{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:33:00Z","timestamp":1792895580712,"version":"4.5.0"},"reference-count":51,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Arterial thromboembolism has been associated with cancer or its treatment. Unlike venous thromboembolism, the incidence and risk factors have not been extensively studied. Here, we investigated the incidence of arterial thromboembolic events (ATEs) in an institutional series of advanced urinary tract cancer (aUTC) treated with cytotoxic chemotherapy. The ATE definition included peripheral arterial embolism\/thrombosis, ischemic stroke and coronary events. A total of 354 aUTC patients were analyzed. Most patients (95.2%) received platinum-based chemotherapy. A total of 12 patients (3.4%) suffered an ATE within a median time of 3.6 months from the start of chemotherapy. The most frequent ATE was ischemic stroke (n = 7). Two ATEs were fatal. The 6-month and 24-month incidence were 2.1% (95% confidence interval [CI]: 0.9\u20134.1) and 3.6% (95% CI: 1.9\u20136.2), respectively. Perioperative chemotherapy increased the risk for ATE by 5.55-fold. Tumors other than UTC and pure non-transitional cell carcinoma histology were also independent risk factors. No association with the type of chemotherapy was found. Overall, ATEs occur in 4.6% of aUTC patients treated with chemotherapy and represent a clinically relevant manifestation. Perioperative chemotherapy significantly increases the risk for ATE. The role of prophylaxis in high-risk groups should be prospectively studied.<\/jats:p>","DOI":"10.3390\/curroncol29090478","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T21:03:51Z","timestamp":1661375031000},"page":"6077-6090","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5996-7262","authenticated-orcid":false,"given":"Aristotelis","family":"Bamias","sequence":"first","affiliation":[{"name":"2nd Propaedeutic Dept of Internal Medicine, National & Kapodistrian University of Athens, ATTIKON University Hospital, Rimini st 1, 12642 Chaidari, Attiki, Greece"},{"name":"Hellenic GU Cancer Group, Evrou st 89, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimon","family":"Tzannis","sequence":"additional","affiliation":[{"name":"2nd Propaedeutic Dept of Internal Medicine, National & Kapodistrian University of Athens, ATTIKON University Hospital, Rimini st 1, 12642 Chaidari, Attiki, Greece"},{"name":"Hellenic GU Cancer Group, Evrou st 89, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-8879","authenticated-orcid":false,"given":"Roubini","family":"Zakopoulou","sequence":"additional","affiliation":[{"name":"Dept of Clinical Therapeutics, National & Kapodistrian University of Athens, ALEXNADRA Hospital, Vas. Sofias Ave 80, 11528 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minas","family":"Sakellakis","sequence":"additional","affiliation":[{"name":"Hellenic GU Cancer Group, Evrou st 89, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Dimitriadis","sequence":"additional","affiliation":[{"name":"Dept of Clinical Therapeutics, National & Kapodistrian University of Athens, ALEXNADRA Hospital, Vas. Sofias Ave 80, 11528 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkistis","family":"Papatheodoridi","sequence":"additional","affiliation":[{"name":"Dept of Clinical Therapeutics, National & Kapodistrian University of Athens, ALEXNADRA Hospital, Vas. Sofias Ave 80, 11528 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7349-0309","authenticated-orcid":false,"given":"Loukianos","family":"Rallidis","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology, National & Kapodistrian University of Athens, ATTIKON University Hospital, Rimini st 1, 12642 Chaidari, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-8977","authenticated-orcid":false,"given":"Panagiotis","family":"Halvatsiotis","sequence":"additional","affiliation":[{"name":"2nd Propaedeutic Dept of Internal Medicine, National & Kapodistrian University of Athens, ATTIKON University Hospital, Rimini st 1, 12642 Chaidari, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tsiara","sequence":"additional","affiliation":[{"name":"Dept of Clinical Therapeutics, National & Kapodistrian University of Athens, ALEXNADRA Hospital, Vas. Sofias Ave 80, 11528 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kaparelou","sequence":"additional","affiliation":[{"name":"Dept of Clinical Therapeutics, National & Kapodistrian University of Athens, ALEXNADRA Hospital, Vas. Sofias Ave 80, 11528 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios","family":"Kostouros","sequence":"additional","affiliation":[{"name":"Oncology Department, Athens General Hospital \u201cG. Gennimatas\u201d, Mesogeion 154, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Barbarousi","sequence":"additional","affiliation":[{"name":"Haematology Division, Alexandra Hospital, Vasilissis Sofias 80, 11528 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Koutsoukos","sequence":"additional","affiliation":[{"name":"Dept of Clinical Therapeutics, National & Kapodistrian University of Athens, ALEXNADRA Hospital, Vas. Sofias Ave 80, 11528 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Fragiadis","sequence":"additional","affiliation":[{"name":"1st Dept of Urology, National & Kapodistrian University of Athens, LAIKON Hospital, Agiou Thoma st 17, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios E.","family":"Dellis","sequence":"additional","affiliation":[{"name":"2nd Dept of Surgery, Aretaieion Academic Hospital, National & Kapodistrian University of Athens, Vas. Sofias Ave 76, 11528 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Anastasiou","sequence":"additional","affiliation":[{"name":"1st Dept of Urology, National & Kapodistrian University of Athens, LAIKON Hospital, Agiou Thoma st 17, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Stravodimos","sequence":"additional","affiliation":[{"name":"1st Dept of Urology, National & Kapodistrian University of Athens, LAIKON Hospital, Agiou Thoma st 17, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Pinitas","sequence":"additional","affiliation":[{"name":"2nd Dept of Urology, National & Kapodistrian University of Athens, Sismanoglio General Hospital, Sismanoglou st 1, 15126 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-1175","authenticated-orcid":false,"given":"Athanasios","family":"Papatsoris","sequence":"additional","affiliation":[{"name":"2nd Dept of Urology, National & Kapodistrian University of Athens, Sismanoglio General Hospital, Sismanoglou st 1, 15126 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Adamakis","sequence":"additional","affiliation":[{"name":"1st Dept of Urology, National & Kapodistrian University of Athens, LAIKON Hospital, Agiou Thoma st 17, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-7404","authenticated-orcid":false,"given":"Ioannis","family":"Varkarakis","sequence":"additional","affiliation":[{"name":"2nd Dept of Urology, National & Kapodistrian University of Athens, Sismanoglio General Hospital, Sismanoglou st 1, 15126 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Fragoulis","sequence":"additional","affiliation":[{"name":"Department of Urology, Athens General Hospital \u201cG. Gennimatas\u201d, Mesogeion 154, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatina","family":"Pagoni","sequence":"additional","affiliation":[{"name":"Oncology Department, Athens General Hospital \u201cG. Gennimatas\u201d, Mesogeion 154, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Matsouka","sequence":"additional","affiliation":[{"name":"Oncology Department, Athens General Hospital \u201cG. Gennimatas\u201d, Mesogeion 154, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Skolarikos","sequence":"additional","affiliation":[{"name":"2nd Dept of Urology, National & Kapodistrian University of Athens, Sismanoglio General Hospital, Sismanoglou st 1, 15126 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios","family":"Mitropoulos","sequence":"additional","affiliation":[{"name":"1st Dept of Urology, National & Kapodistrian University of Athens, LAIKON Hospital, Agiou Thoma st 17, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Doumas","sequence":"additional","affiliation":[{"name":"Department of Urology, Athens General Hospital \u201cG. Gennimatas\u201d, Mesogeion 154, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Deliveliotis","sequence":"additional","affiliation":[{"name":"2nd Dept of Urology, National & Kapodistrian University of Athens, Sismanoglio General Hospital, Sismanoglou st 1, 15126 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Constantinides","sequence":"additional","affiliation":[{"name":"1st Dept of Urology, National & Kapodistrian University of Athens, LAIKON Hospital, Agiou Thoma st 17, 11527 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Dept of Clinical Therapeutics, National & Kapodistrian University of Athens, ALEXNADRA Hospital, Vas. Sofias Ave 80, 11528 Athens, Attiki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of Arterial Thromboembolism in Patients With Cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.24325","article-title":"Association between incident cancer and subsequent stroke","volume":"77","author":"Navi","year":"2015","journal-title":"Ann. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2011.09.015","article-title":"Risk of coronary heart disease in patients with cancer: A nationwide follow-up study from Sweden","volume":"48","author":"Ji","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2012.01.005","article-title":"Risk of haemorrhagic and ischaemic stroke in patients with cancer: A nationwide follow-up study from Sweden","volume":"48","author":"Ji","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2017.07.719","article-title":"Cancer and clot: Between a rock and a hard place","volume":"70","author":"Yeh","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bang, O.Y., Chung, J.W., Lee, M.J., Kim, S.J., Cho, Y.H., Kim, G.M., Chung, C.-S., Lee, K.H., Ahn, M.-J., and Moon, G.J. (2016). Cancer cell-derived extracellular vesicles are associ- ated with coagulopathy causing ischemic stroke via tissue factor-independent way: The OASIS-CANCER Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159170"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0034-1370765","article-title":"NETosis: A new factor in tumor progression and cancer-associated thrombosis","volume":"40","author":"Demers","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood-2019-01-894261","article-title":"If Trousseau had a stroke","volume":"133","author":"Khorana","year":"2019","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cncr.20893","article-title":"Prospective evaluation of major vascular events in patients with non-small cell lung carcinoma treated with cisplatin and gemcitabine","volume":"103","year":"2005","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/cncr.29801","article-title":"The high incidence of vascular thromboembolic events in advanced urothelial cancer treated with platinum chemotherapy agents","volume":"122","author":"Tully","year":"2016","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Lyman","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: The prospective COMPASS\u2013Cancer Associated Thrombosis Study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/CIRCULATIONAHA.111.018820","article-title":"Global variation in the relative burden of stroke and ischemic heart disease","volume":"124","author":"Kim","year":"2011","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.amjcard.2013.08.019","article-title":"Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention","volume":"112","author":"Velders","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.0000000000000539","article-title":"Recurrent thromboembolic events after ischemic stroke in patients with cancer","volume":"83","author":"Navi","year":"2014","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/BLC-170146","article-title":"Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and Prevention","volume":"4","author":"Zareba","year":"2018","journal-title":"Bladder Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","article-title":"Risk of venous thromboembolism in patients with cancer treated with cisplatin: A systematic review and meta-analysis","volume":"30","author":"Seng","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0022-5347(01)62232-8","article-title":"High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy","volume":"160","author":"Czaykowski","year":"1998","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/annonc\/mds583","article-title":"Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine\/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: A Hellenic Cooperative Oncology Group study (HE16\/03)","volume":"24","author":"Bamias","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bjc.6602378","article-title":"Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: A phase II study","volume":"92","author":"Ardavanis","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/annonc\/mdj079","article-title":"Systemic chemotherapy in inoperable or metastatic bladder cancer","volume":"17","author":"Bamias","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1053\/j.seminoncol.2006.12.008","article-title":"Chemotherapy for metastatic or unresectable bladder cancer","volume":"34","author":"Bellmunt","year":"2007","journal-title":"Semin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.urolonc.2004.01.002","article-title":"A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer","volume":"22","author":"Kaufman","year":"2004","journal-title":"Urol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/CAD.0b013e3280126603","article-title":"Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study","volume":"18","author":"Lin","year":"2007","journal-title":"Anticancer. Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cncr.21604","article-title":"The combination of gemcitabine an carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group","volume":"106","author":"Bamias","year":"2006","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W","article-title":"Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma","volume":"80","author":"Bellmunt","year":"1997","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-5347(01)64490-2","article-title":"Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer","volume":"158","author":"Kyriakakis","year":"1997","journal-title":"J. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"Sengelov","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cncr.20123","article-title":"Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium","volume":"100","author":"Dreicer","year":"2004","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/CAD.0000000000000297","article-title":"Treatment of relapsed urothelial bladder cancer with vinflunine: Real-world evidence by the Hellenic Genitourinary Cancer Group","volume":"27","author":"Pistamaltzian","year":"2016","journal-title":"Anticancer. Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1023\/A:1008379500436","article-title":"Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group","volume":"10","author":"Dimopoulos","year":"1999","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.radonc.2011.06.016","article-title":"Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden","volume":"100","author":"McGale","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1161\/STROKEAHA.111.615534","article-title":"Lung cancer and incidence of stroke: A population-based cohort study","volume":"42","author":"Chen","year":"2011","journal-title":"Stroke"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.ijrobp.2009.09.061","article-title":"Cardiovascular morbidity after radiotherapy or chemoradiation in patients with cervical cancer","volume":"78","author":"Maduro","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/bjc.2011.361","article-title":"Increase in stroke risk in patients with head and neck cancer: A retrospective cohort study","volume":"105","author":"Chu","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-08-3392","article-title":"Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma","volume":"107","author":"Moser","year":"2006","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1336","DOI":"10.1097\/MD.0000000000001336","article-title":"Risk of ischemic stroke in patients with gastric cancer: A nationwide population-based cohort study","volume":"94","author":"Kuan","year":"2015","journal-title":"Medicine"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kuan, A.-S., Teng, C.-J., Wu, H.-H., Su, V.-Y., Chen, Y.-T., Chien, S.-H., Yeh, C.-M., Hu, L.-Y., Chen, T.-J., and Tzeng, C.-H. (2014). Risk of ischemic stroke in patients with ovarian cancer: A nationwide population-based study. BMC Med., 12.","DOI":"10.1186\/1741-7015-12-53"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/cam4.986","article-title":"Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: Incidence, associative factors, and effect on survival","volume":"6","author":"Ramos","year":"2017","journal-title":"Cancer Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eururo.2014.01.009","article-title":"Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides","volume":"67","author":"Reardon","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/STR.0000000000000046","article-title":"Guidelines for the primary prevention of stroke: A statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Meschia","year":"2014","journal-title":"Stroke"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/CIR.0000000000000381","article-title":"Preventing and experiencing ischemic heart disease as a woman: State of the science: A scientific statement from the American Heart Association","volume":"133","author":"McSweeney","year":"2016","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjmed.2018.04.037","article-title":"Arterial ischemic events are a major complication in cancer patients with venous thromboembolism","volume":"131","author":"Brenner","year":"2018","journal-title":"Am. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/9\/478\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:14:52Z","timestamp":1760141692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/9\/478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["curroncol29090478"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29090478","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}